News
News about Imperial technology development and commercial deals
Filter by theme
![Accelerated development of a potential treatment for cystic fibrosis](https://cdn.statically.io/img/imperial.tech/wp-content/uploads/2021/10/newseventsimage_1634653774994_mainnews2012_x4-400x284.jpg)
Accelerated development of a potential treatment for cystic fibrosis
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Read more
![Natural Killer – licensing a cell therapy](https://cdn.statically.io/img/imperial.tech/wp-content/uploads/2021/09/karadimitris1-mobile--400x284.webp)
Natural Killer – licensing a cell therapy
Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Read more
![Imperial partner Apollo receives £100m to boost medical research at leading unis](https://cdn.statically.io/img/imperial.tech/wp-content/uploads/2021/10/newseventsimage_1623958345088_mainnews2012_x1-400x284.jpg)
Imperial partner Apollo receives £100m to boost medical research at leading unis
Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Read more
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.